Why precise subtyping matters
Blood cancers are not one disease. AML, ALL, CML, CLL, Hodgkin lymphoma, DLBCL, follicular lymphoma, mantle cell lymphoma, Burkitt lymphoma and myeloma each have distinct biology and treatment. Subtyping uses morphology, immunophenotype, cytogenetics and molecular testing. A treatment plan built on an incomplete diagnosis can be ineffective or unnecessarily toxic.
Related: Haematology → · Dr. Sachita Baniya profile → · All conditions →
Treatment options discussed honestly
Options may include chemotherapy, targeted therapy, immunotherapy, radiotherapy, autologous or allogeneic transplant and CAR-T. Each has benefits, limitations and supportive-care needs. Dr. Baniya explains treatment intent — whether the aim is cure, disease control or symptom relief — and what monitoring will be required.
- Risk-adapted chemotherapy and targeted therapy
- Autologous, allogeneic and haplo-identical transplant
- CAR-T eligibility and referral
- Measurable residual disease monitoring
- Supportive care and survivorship planning
Where to start
Bring the pathology report, bone marrow and flow cytometry reports, cytogenetics, molecular results, imaging and treatment history. A second opinion is reasonable when the diagnosis is uncertain or options are closely balanced. Dr. Baniya consults at Kathmandu Neurology Clinic & Cognitive Center, Durbar Marg, and also practises at Kathmandu Cancer Center (KCC) Nepal, Civil Service Hospital, Kathmandu, and Advanced Care Hospital.